OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Oct 4, 2021 • 17min
S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.
Sep 30, 2021 • 18min
S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices
Sep 27, 2021 • 27min
S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III NSCLC.
Sep 23, 2021 • 16min
S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.
Sep 20, 2021 • 16min
S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.
Sep 16, 2021 • 29min
S5 Ep42: Neel on Maximizing Research Strides in Oncology
Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.
Sep 13, 2021 • 17min
S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer
Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.
Sep 9, 2021 • 17min
S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer
Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
Sep 6, 2021 • 17min
S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC
Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuances regarding the timing of treatment in this disease.
Sep 2, 2021 • 18min
S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, and future research directions in the field.
